Open Access

miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A

  • Authors:
    • Fei Tian
    • Huihan Wang
    • Huanxin Ma
    • Yuan Zhong
    • Aijun Liao
  • View Affiliations

  • Published online on: July 6, 2020     https://doi.org/10.3892/ijmm.2020.4670
  • Pages: 1155-1165
  • Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multiple myelomas (MM) are the second most common haematological malignancy, for which no curative treatments have been reported to date. MicroRNAs (miRNAs or miRs) have recently been shown to be involved in the proliferation of MM cells. However, the molecular mechanisms through which miRNAs regulate migration and angiogenesis in MM are poorly understood. Accordingly, the present study evaluated the role of miR‑144‑3p in MM. miR‑144‑3p exhibited a lower expression in patients with MM and in MM cell lines compared with normal cells (mononuclear cells derived from bone marrow). The transfection of miR‑144‑3p into MM cells inhibited proliferation, migration and angiogenesis, and induced cell cycle arrest and apoptosis compared to the control cells. Furthermore, miR‑144‑3p suppressed the transcription and translation of the myocyte enhancer factor 2A (MEF2A) gene and disrupted the expression of vascular endothelial growth factor. The knockdown of MEF2A significantly inhibited the proliferation, migration and angiogenesis of MM cells. However, the overexpression of MEF2A reversed these effects. On the whole, the findings of the present study demonstrate that miR‑144‑3p exerts antitumour effects by downregulating MEF2A to inhibit the proliferation, migration and angiogenesis of MM cells. This suggests that the miR‑144‑3p/MEF2A interaction may prove to be a potential therapeutic target for MM.

Related Articles

Journal Cover

September-2020
Volume 46 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tian F, Wang H, Ma H, Zhong Y and Liao A: miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A. Int J Mol Med 46: 1155-1165, 2020
APA
Tian, F., Wang, H., Ma, H., Zhong, Y., & Liao, A. (2020). miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A. International Journal of Molecular Medicine, 46, 1155-1165. https://doi.org/10.3892/ijmm.2020.4670
MLA
Tian, F., Wang, H., Ma, H., Zhong, Y., Liao, A."miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A". International Journal of Molecular Medicine 46.3 (2020): 1155-1165.
Chicago
Tian, F., Wang, H., Ma, H., Zhong, Y., Liao, A."miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A". International Journal of Molecular Medicine 46, no. 3 (2020): 1155-1165. https://doi.org/10.3892/ijmm.2020.4670